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Objectives
To develop a consensus statement on current best practice of
active surveillance (AS) in the UK, informed by patients and
clinical experts.
Subjects and Methods
A consensus statement was drafted on the basis of three
sources of data: systematic literature search of national and
international guidelines; data arising from a Freedom of
Information Act request to UK urology departments
regarding their current practice of AS; and survey and
interview responses from men with localized prostate cancer
regarding their experiences and views of AS. The Prostate
Cancer UK Expert Reference Group (ERG) on AS was then
convened to discuss and refine the statement.
Results
Guidelines and protocols for AS varied significantly in terms of
risk stratification, criteria for offering AS, and protocols for AS
between and within countries. Patients and healthcare
professionals identified clinical, emotional and process needs
for AS to be effective. Men with prostate cancer wanted more
information and psychological support at the time of discussing
AS with the treating team and in the first 2 years of AS, and a
named healthcare professional to discuss any questions or
concerns they had. The ERG agreed 30 consensus statements
regarding best practice for AS. Statements were grouped under
headings: ‘Inclusion/Exclusion Criteria’; ‘AS follow-up
protocol’ and ‘When to stop AS’.
Conclusion
Significant variation currently exists in the practice of AS in
the UK and internationally. Men have clear views on the level
of involvement in treatment decisions and support from their
treating professionals when receiving AS. The Prostate Cancer
UK AS ERG has developed a set of consensus statements for
best practice in AS. Evidence for best practice in AS, and the
use of multiparametric magnetic resonance imaging in AS, is
still evolving, and further studies are needed to determine
how to optimize AS outcomes.
Keywords
active surveillance, clinical consensus, guidelines, #PCSM,
#ProstateCancer, #uroonc
Introduction
Prostate cancer incidence in high-income countries, including
the UK, has increased by up to 300% in recent decades, while
prostate cancer mortality has remained largely static [1]. The
rise in incidence has been largely driven by the detection of
more early-stage and indolent cancers, and the ageing
population [2].
Active surveillance (AS) has evolved as a viable approach for
some men with prostate cancer, and involves regular
monitoring for signs of cancer progression in patients with
low- to intermediate-risk, localized prostate cancer, in order
to defer or avoid radical treatment [3]. Recent studies, such
as PROTECT and PIVOT, have shown no difference in 10-
year mortality between patients receiving radical treatment
and those undergoing monitoring, although it should be
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noted that the monitoring in these studies differed from
modern AS practice [4,5].
Men with low-risk prostate cancer, and some men with
intermediate-risk prostate cancer, are encouraged to
consider AS after initial diagnosis. In the UK, the uptake
of AS for low-risk prostate cancer has increased with the
publication of the 2008 National Institute for Health and
Care Excellence (NICE) guidelines recommending AS as the
preferred option for men with low-risk prostate cancer
[6,7]. The latest publication from the National Prostate
Cancer Audit suggests that the rate of potential
overtreatment reduced from 12% in April 2014 to March
2015 compared with 8% in April 2015 to March 2016 [8].
Perceptions about treatment efficacy and side effects are
important factors for men in deciding between management
options [9]. Despite variation in AS protocols and inclusion
criteria, meta-analyses and systematic reviews have
suggested a higher prevalence of anxiety in men
undergoing AS compared to the general population [10,11].
Provision of extra information and psychological support
for men on AS have consistently been highlighted as areas
of need for improvement [9,12–14]. There is a scarcity of
literature on the subject of AS, and studies tend not to
reflect current UK practice.
Active surveillance clinical guidelines and implementation of
AS varies between and within countries [15]. The
‘Movember’-funded Global Action Project 3 on Active
Surveillance (GAP3) has the largest pooled cohort of men on
AS, incorporating over 14 000 patients across 25 centres
worldwide [16]. GAP3 aims to use the data gathered from
this cohort to inform AS guidelines internationally on the
selection and monitoring of patients with low-risk prostate
cancer. The group has also published an expert consensus
document on the semantics used in AS, to facilitate
international discussion [17].
Multiparametric MRI (mpMRI) is established in the UK as a
useful tool to aid prostate cancer diagnosis, and it is
recommended in the 2014 NICE guidelines for the
assessment of men, both early in surveillance, and during
follow-up [18]. The exact role of mpMRI in AS is under
discussion, including the possibility that it can be used to
avoid repeat biopsies in some men [19–21]. Trials with long-
term follow-up incorporating mpMRI within AS protocols,
such as the SPCG17: Prostate Cancer Active Surveillance
Trigger Trial (clinicaltrials.gov identifier NCT02914873), are
ongoing.
Prostate Cancer UK commissioned the present research to
develop an in-depth understanding of current AS practice
for men with prostate cancer, to inform discussions around
the role of AS in the treatment pathway for localized
prostate cancer, and to define current best practice in AS
in the UK.
Subjects and Methods
The present consensus statement was informed by a
systematic literature search of current national and
international guidelines and protocols. These were analysed
for commonality of practice, thresholds for inclusion, follow-
up intensity and triggers used to switch men to radical
treatment, whether surgery or radiotherapy. A Freedom of
Information Act request to urology departments across the
UK regarding their current practice of AS was submitted in
July 2017 and included questions about each department’s AS
protocol, inclusion criteria for AS, use of mpMRI at diagnosis
and follow-up for men on AS. A PubMed literature search
for AS protocols incorporating mpMRI was also performed.
Men with localized prostate cancer were recruited through
self-selection to complete an online survey of their
experiences and views of AS via Prostate Cancer UK social
media accounts, prostate cancer support groups, volunteer
networks and direct email invitations. Prostate Cancer UK
staff and expert patients developed the questionnaire content
(Appendix S1). Quantitative survey data obtained were
analysed using descriptive statistics. In-depth, qualitative
interviews of men with prostate cancer on AS and men
without prostate cancer were undertaken to further
understand their views and experiences of AS. Interviewees
were recruited using a qualitative market research fieldwork
agency (Criteria), using a screener questionnaire. In-depth
interviews were expanded to include clinicians and academics
with expertise in prostate cancer and AS.
A set of consensus statements on the best practice approach
to AS, incorporating mpMRI, was developed based on
existing guidelines, protocols used by UK Urology
departments, and survey data from men with localized
prostate cancer. The views and experiences of men were also
used to develop consensus statements to address the support
and information needs of men during diagnosis, treatment
decision-making and during AS follow-up. The draft
consensus statements were then discussed at a face-to-face
meeting of a subgroup of the Prostate Cancer UK Active
Surveillance Expert Reference Group (ERG). The full ERG
consisted of 27 members, selected because of their peer-
reviewed publications and expertise in prostate cancer
diagnosis, and/or AS inclusion and management. This group
worked virtually to support the research and development of
draft clinical consensus statements. Membership covered the
following professions and backgrounds: urology; oncology;
radiology; pathology; general practice; clinical specialist
nursing; clinical psychology; research; patient experts; and
representatives from relevant professional bodies – the BAUS,
British Association of Urological Nurses, Royal College of
Radiologists, Royal College of Pathologists and Royal College
of General Practitioners. A subgroup of the ERG (ERG Panel)
consisting of 14 members (12 clinicians and two patient
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experts) was convened on 8 March 2018 for a further round
of review of the consensus statements. The ERG
Panel included three urologists, two pathologists, two
radiologists, two GPs, one expert patient, one patient group
representative, one uro-oncology clinical nurse specialist, one
urology advanced nurse practitioner, and one researcher. The
panel was chaired and observed by representatives from
Prostate Cancer UK. The ERG Panel reviewed evidence,
discussed the draft consensus statements and agreed on the
final clinical consensus statement.
Results
Active Surveillance Guidelines
International guidelines for AS were identified from the UK,
Europe, Canada and North America. These guidelines
demonstrated variation in a number of key areas. In terms of
risk stratification, the guidelines included different risk
categories and used different key clinical characteristics to
determine a patient’s risk. mpMRI was only addressed in half
of the guidelines identified, and recommendations for using
mpMRI varied greatly. NICE guidance and the Canadian
Urological Association guidelines were the only two to
consider recommending AS to patients with intermediate-risk
prostate cancer. Protocols for AS follow-up also showed
significant heterogeneity in terms of frequency of follow-up
and PSA testing, use of mpMRI and whether to perform
surveillance biopsies (Table 1).
Freedom of Information Request
A total of 92.4% of acute hospital trusts, health boards, and
health and social care boards (145/157) in the UK responded
to the Freedom of Information request. Of these 145
providers, 58 (40.0%) stated that they followed current NICE
guidance (Prostate cancer: diagnosis and management Clinical
guideline [CG175]), and 48.3% (70/145) either followed an
adapted version of NICE guidance or a local protocol. Ten
providers (6.9%) stated they had no protocol in place, and
3.4% (5/145) followed an alternative external protocol.
The most commonly cited factors in assessing men for AS
suitability were PSA level, clinical stage and Gleason score,
although there was large variability among providers in the
upper limit for clinical stages deemed suitable for AS (T1–T2C).
Variability also occurred in utilization of family history and
ethnicity as inclusion criteria. Of the trusts who provided an
answer for these questions, 50.8% of providers (62/122) stated
that family history was used as a separate inclusion criterion,
whereas 40.2% of providers (49/122) did not use family history
to decide AS suitability. A total of 60.5% of providers (72/119)
responded that black ethnicity was used as an inclusion
criterion to determine AS suitability. Furthermore, 68.6% of
providers (83/121) stated that calendar age was used as an
inclusion criterion, and 83.3% of providers (90/108) used life
expectancy to determine AS suitability. Use of mpMRI, biopsy
and re-biopsy methods also varied, but this could potentially be
a result of shifting UK practices.
Patient Survey
A total of 744 men with prostate cancer from across the UK
completed the online survey; 619 (83.2%) of these men had
been diagnosed with localized disease. Of those who answered
the screening questions 95.8% (362/378) were white British,
and 70.6% (267/378) were diagnosed between the ages of 55–
69 years. Approximately 40% of patients diagnosed over the
last 5 years did not recall being presented with AS as a
treatment option. Of the survey respondents who had
received AS as a treatment, 62.0% (163/263) were still on an
AS treatment programme, whilst 27.8% (73/263) of survey
respondents had left AS as a result of cancer progression, and
8.0% (21/263) through patient choice.
Concerns about the risk of developing metastases (73.7%
[202/274]) outweighed the ability to avoid/delay treatment to
avoid side effects (47.0% [118/251]) for men faced with the
option of undergoing AS. ‘Discussion with a specialist about
AS’ (72.3% [289/400]), ‘Access to test results and explanations
of the results’ (70.3% [281/400]), and ‘A named healthcare
professional to discuss any questions or concerns’ (66.3%
[265/400]) were the most commonly selected options for
what should be available for men on AS.
Interviews with Patients, Clinicians and Academics
Twelve face-to-face and eight telephone interviews were
conducted with a range of relevant stakeholders, including
men with and without prostate cancer and healthcare
professionals with expertise in AS. Patients and healthcare
professionals identified clinical, emotional and process needs
for AS to be effective. The initial consultation explaining the
diagnosis and treatment options appeared to be crucial for
men’s opinion of AS. Men with prostate cancer wanted more
objective information and emotional support at the time of
discussing AS with the treating team and in the first 2 years
of AS. A central driver for men to choose AS was the
avoidance of side effects from radical treatment and enabled
them to ‘play down’ their cancer diagnosis, whilst, for others,
AS appeared to go against the ‘find it early and treat it’
narrative. Continuity of care, seamless follow-up appointment
bookings, and clarity on test results and trends were key
themes for men with positive experiences of AS.
Consensus Statement
The panel agreed a consensus statement regarding the best
practice approach to AS. Statements were grouped under
headings: ‘Inclusion/Exclusion criteria’; ‘AS follow-up
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protocol’ and ‘When to stop AS’. The full list of consensus
statements can be found in Table 2.
Discussion
The Prostate Cancer UK Active Surveillance ERG assessed
data from a review of international AS guidelines, a Freedom
of Information request to UK Urology departments, and
quantitative and qualitative data from men with prostate
cancer to inform a clinical consensus statement on the best
practice of AS. This research found significant variation in
current guidelines and protocols for AS in men with low- and
intermediate-risk prostate cancer internationally, with
variation in practice across the UK. Interviews and surveys
conducted with men with prostate cancer elicited key factors
in their treatment decision-making concerning AS, and
identified their information and support needs for men
receiving AS. Significant gaps in the literature surrounding
the appropriate timing of mpMRI and other follow-up tests
for men on AS were identified.
Active surveillance is increasingly being used for men with
prostate cancer, in the context of rising rates of diagnosis of
Table 2 Prostate Cancer UK Expert Reference Group on active surveillance (AS) consensus statements on best practice of AS.
Inclusion criteria
Gleason score: 3 + 3 – primary treatment recommended is AS
Consider AS for men with prostate cancer with the following characteristics:
Gleason score: 3 + 4 AND
mpMRI T stage: ≤T2* AND
Biopsy and MRI should be concordant AND
PSA density of ≤0.2 ng/mL2 AND
Men enrolled onto AS should be considered fit for radical treatment
Note: Men who are suitable for AS should have access to specialist information and support during the decision-making stage. Patient priorities should be considered, and all
potential treatments, side effects and risks should be discussed prior to AS enrolment.
*For men not suitable for mpMRI, clinical T-stage should be used.
Exclusion criteria
Men not suitable for AS include:
Gleason score ≥4 + 3 with pattern 4 disease in > 2 cores or >5 mm of cancer in a single core** OR
mpMRI T stage: ≥T3a*
*For men not suitable for mpMRI, clinical T-stage should be used.
** Very-low- volume Gleason 4 + 3 – consider re-biopsy if patient wishes to have AS. [Low volume defined as Gleason 4 pattern disease in 1 or 2 cores or <5 mm of cancer in
any core.]
AS follow-up protocol
Men on AS should have access to a clinical specialist nurse
Men should be offered and have access to support /counselling during their time on AS
Year 1 of AS
Men should be provided with a personalized AS plan, including details of PSA interval, individualized PSA threshold for re-assessment and follow-up. The personalized plan
should be communicated to the patient’s GP.
A repeat PSA test should be carried out in line with the recommended PSA interval and threshold† communicated by the patient’s Urology Consultant within the personalized
AS plan.
†The factors that will influence a patient’s PSA interval could include: PSA history; mpMRI results; and PSA density.
If the patient’s individualized PSA threshold is breached then the GP should check a mid-stream urine specimen for infection, and re-check the PSA after 6 weeks if the urine
is negative for infection. If the PSA threshold remains breached, then the GP should re-refer the patient for further diagnostics.
A repeat mpMRI scan should be conducted at 12 months after baseline.
Consider deferring routine 12-month biopsy if patient is considered low risk of progression or re-classification, e.g. stable mpMRI and PSA.
A DRE should be performed at 12 months where mpMRI is contraindicated.
A repeat biopsy should be offered when mpMRI shows a suspicion of progression or if there is evidence of PSA changes (e.g. the individualized PSA threshold is breached).
Year 2+ of AS
Men should be provided with an updated personalized AS plan that should be communicated to their GP.
A repeat PSA test should be carried out in line with the recommended PSA interval and threshold† communicated by the patient’s Urology Consultant within the personalized
AS plan.
†The factors that will influence a patient’s PSA interval could include: PSA history; mpMRI results; and PSA density.
If the patient’s individualized PSA threshold is breached then the GP should check a mid-stream urine specimen for infection, and re-check the
PSA after 6 weeks if the urine is negative for infection. If the PSA threshold remains breached, then the GP should re-refer
the patient for further diagnostics.
A repeat mpMRI scan should be considered if a lesion was visible at baseline or the PSA rises and breaches the individualized PSA threshold.
A DRE should be considered on an individual basis.
A repeat biopsy should be offered when mpMRI shows a suspicion of progression.
Clinical assessment of suitability for radical treatment should be reviewed periodically.
When to stop AS
The decision to change from AS to radical treatment or watchful waiting should be made in light of the individual man’s personal preferences, in addition to clinical features,
comorbidities, functional impairment (i.e. e-Frailty index) and life expectancy.
AS, active surveillance; mpMRI, multiparametric MRI. The AS follow-up protocol acknowledges: that there are limitations of using PSA kinetics as a predictor of biopsy
reclassification, hence, some men, especially those who are risk averse, may opt for an interval biopsy even if MRI images and PSA tests remain stable; that it is not clear, from
currently available evidence, what the ideal intervals for AS follow-up should be; and that the recommended surveillance protocol remains dynamic and will respond to evolving
evidence.
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clinically insignificant prostate cancer [1]. Risk stratification
across international guidance and local AS protocols in the UK
mostly use PSA, clinical T-stage and Gleason score, with
limited current use of mpMRI to varying degrees. Only two
current guidelines for AS include recommendations to consider
AS for some men with intermediate-risk prostate cancer
[22,23]. The ERG also recommended offering AS for a subset of
men with intermediate-risk prostate cancer using a strictly
defined set of clinical criteria, although this may have differed if
more panel members were drawn from outside the UK.
Follow-up protocols for AS is an area where there is a much
greater need for clinical consistency. The use of PSA, DRE
and repeat biopsy for men receiving AS varies widely. The
role of mpMRI in monitoring disease progression is also an
evolving field, and the evidence base is currently limited. A
UK study of AS incorporating baseline biopsy, annual
mpMRI, 3-monthly PSA testing, and re-biopsy at 1 and
3 years after baseline showed mpMRI changes were the main
trigger for detecting prostate cancer progression, but per-
protocol re-biopsy also detected changes not picked up by
mpMRI or PSA [24]. A scarcity of quality AS treatment trials
and agreed international approaches hampered the
development of clear clinical consensus by the ERG.
In an attempt to fill the evidence void for best practice in AS,
the ERG made some patient-centred and innovative
recommendations for AS where consensus could be reached
(Table 2). A personalized AS plan specifying PSA frequencies
and thresholds for re-investigation, should be developed by the
treating urologist taking into account individual patient factors
(e.g. age, comorbidities) and their previous total PSA and PSA
density. This plan then needs to be shared with the patient and
their GP to ensure all parties are clear on the individualized
approach to AS for the patient. There is a strong emphasis on
providing men who are offered AS with specialist information
and support through the decision-making process.
This process to develop and agree clinical consensus
statements on best practice for AS was informed by a wide
range of data sources, bringing together the evidence from
national guidelines, expert opinion and, crucially, the views of
men with prostate cancer. Incorporating patient’s views on
AS through multiple triangulated sources (surveys, interviews
and ERG participation) adds to the strength of the consensus
statements [25]. This robust evidence base was employed to
draft the clinical statements, which were then interrogated
and debated by experts in the field to achieve consensus.
The major limitation of the present research is the lack of
high-quality, large multicentre studies on which to base the
consensus statements regarding the utility of mpMRI in AS
risk stratification and follow-up, the optimal frequency of
mpMRI, and thresholds/triggers for biopsy or treatment for
men on AS. The aim of the GAP3 cohort study is to
provide useful insights into the selection and monitoring of
men for AS, and the PRECISE recommendations give a
framework for reporting MRI in AS to aid data collection in
future studies [26]. Consensus was not reached amongst the
ERG on a specified frequency of repeat biopsy for men on
AS, but it was agreed that this could be informed by
evidence of change in PSA or mpMRI findings. This
approach could potentially miss some tumours, as
highlighted in the PROMIS [27] and PROTECT [4] trials,
but has also been recommended in the recently published
draft update of NICE guidance [28].
Significant variation currently exists in AS internationally
and within the UK. Men have clear views on their level of
involvement in treatment decisions and on support from
their treating professionals if they are undergoing AS. The
Prostate Cancer UK Active Surveillance ERG has developed
a set of consensus statements to try and guide standards for
AS going forward. Evidence for best practice in AS is still
evolving. Information and support needs for men receiving
AS must be clearly understood, and further prostate cancer
treatment trials are needed to determine how to optimize
AS outcomes.
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